CELULARITY INC.

Analyst Reco. Celularity Inc.

Equities

CELU

US1511902041

Delayed Nasdaq Other stock markets 15:03:25 29/04/2024 BST			5-day change	1st Jan Change
3.03 ^USD	+0.33%		-0.65%	+22.88%

03-26	Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L	CI
03-20	Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Lowers Price Target on Celularity to $2.50 From $15, Maintains Buy Rating	30/01/23	MT
Morgan Stanley Downgrades Celularity to Underweight From Equalweight, Adjusts Price Target to $1 From $5	30/01/23	MT
Oppenheimer Downgrades Celularity to Perform From Outperform, Removes $6 Price Target	22/12/22	MT
Oppenheimer Adjusts Celularity Price Target to $6 From $8, Maintains Outperform Rating	14/11/22	MT
Morgan Stanley Trims Celularity's Price Target to $5 From $8, Keeps Equalweight Rating	12/09/22	MT
Alliance Global Partners Initiates Coverage on Celularity With Buy Rating, $15 Price Target	25/08/22	MT
Truist Securities Trims Price Target on Celularity to $6 From $10, Reiterates Hold Rating	23/08/22	MT
Oppenheimer Adjusts Celularity Price Target to $8 From $10, Maintains Outperform Rating	11/08/22	MT
HC Wainwright Starts Celularity at Buy With $15 Price Target	22/06/22	MT
Truist Securities Downgrades Celularity to Hold From Buy	06/04/22	MT
Oppenheimer Initiates Celularity With Outperform Rating, $9 Price Target	28/01/22	MT
Celularity Stock Drops as Morgan Stanley Initiates Ratings Coverage at Equal-Weight	24/11/21	MT
Morgan Stanley Starts Celularity at Equal-Weight With $9 Price Target	24/11/21	MT
CELULARITY : Truist Securities Initiates Celularity Class at Buy Rating With $12 Price Target	19/10/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer